NEWSROOM
News & Stories
Newsroom
Press Releases
Agendiaโs MammaPrint First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients
Clinical high-risk patients with a low-risk MammaPrintยฎ result, including 48 percent node-positive, had five-year distant metastasis-free survival rate in excess of 94 percent, whether randomized to receive adjuvant chemotherapy or not MammaPrint could change clinical Read More
MINDACT results will be presented during the AACR Annual Meeting 2016
ย ย ย ย ย ย ย ย ย ย EORTC (European Organisation for Research and Treatment of Cancer), BIG (Breast International Group), and Agendia are pleased to announce that the โPrimary analysis of the EORTC 10041/ Read More
Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer Conference as a Prelude to Upcoming MINDACT Trial Findings
Company will also host a lunch symposium on genomic assays and their clinical relevance at the 2016 Miami Breast Cancer Conference (MBCC) IRVINE, CA and AMSTERDAM โ Agendia, Inc., a world leader in personalized medicine Read More